A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Figueiredo, Amarilis [1 ]
Atkins, Harold [1 ,2 ,3 ,4 ]
Mallick, Ranjeeta [5 ,6 ]
Kekre, Natasha [1 ,2 ,3 ,4 ]
Kew, Andrea [2 ,3 ,4 ]
McCurdy, Arleigh [1 ,3 ,4 ]
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Ottawa Hosp, Div Hematol, Ottawa, ON, Canada
[3] Ottawa Hosp, Dept Med, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol, Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4519.4519
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4519
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
    Jian, Yuan
    Chang, Long
    Shi, Ming-Xia
    Sun, Ying
    Chu, Xiao-Xia
    Xue, Hua
    Huang, Wen-Rong
    Shen, Xu-Liang
    Ma, Jie
    Jia, Guo-Rong
    Feng, Ya-Qing
    Xi, Zhen-Fang
    Zhao, Yan-Hong
    Ma, Yan-Ping
    Xiao, Jing
    Ma, Guang-Yu
    Wang, Qing-Ming
    Bao, Li
    Dong, Yu-Jun
    Zhou, He-Bing
    Sun, Chun-Yan
    Su, Guo-Hong
    Yan, Yan
    Qimuge, Sai-Yin
    Su, Li-Ping
    Sun, Jing-Nan
    Tian, Wei-Wei
    Sun, Xiu-Li
    Ing, Hong-Mei
    Gao, Da
    Chen, Wen-Ming
    Li, Jian
    Gao, Wen
    BLOOD ADVANCES, 2023, 7 (24) : 7581 - 7584
  • [42] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (05) : 679 - 686
  • [43] Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [44] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)
    Roussel, Murielle
    Moreau, Philippe
    Hebraud, Benjamin
    Laribi, Kamel
    Jaccard, Arnaud
    Dib, Mamoun
    Slama, Borhane
    Dorvaux, Veronique
    Royer, Bruno
    Frenzel, Laurent
    Zweegman, Sonja
    Klein, Saskia K.
    Broijl, Annemiek
    Jie, Kon-Siong
    Wang, Jianping
    Vanquickelberghe, Veronique
    Boer, Carla de
    Kampfenkel, Tobias
    Gries, Katharine S.
    Fastenau, John
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883
  • [45] Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Moon, Joon Ho
    Sohn, Sang Kyun
    Jung, Sung-Hoon
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD, 2011, 118 (21) : 815 - 815
  • [46] Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
    Ashrafi, Farzaneh
    Moghaddas, Azadeh
    Darakhshandeh, Ali
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (01) : 56 - 59
  • [47] Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients
    Yi, Shuhua
    Xiong, Wenjie
    Wang, Yi
    Lv, Rui
    Li Zengjun
    Wei Liu
    Wang, Tingyu
    Gang, An
    Deng, Shuhui
    Xu, Yan
    Sui, Weiwei
    Zou, Dehui
    Qiu, Lugui
    BLOOD, 2019, 134
  • [48] Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
    Reeder, Craig B.
    Reece, Donna E.
    Kukreti, Vishal
    Mikhael, Joseph R.
    Chen, Christine
    Trudel, Suzanne
    Laumann, Kristina
    Vohra, Harjot
    Fonseca, Rafael
    Bergsagel, P. Leif
    Leis, Jose F.
    Tiedemann, Rodger
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (04) : 563 - 565
  • [49] Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma
    Kropff, Martin
    Liebisch, Peter
    Wand, Hannes
    Weisel, Katja
    Gann, Claudia-Nanette
    Knop, Stefan
    Einsele, Hermann
    BLOOD, 2007, 110 (11) : 1053A - 1053A
  • [50] A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
    Ocio, Enrique M.
    Bringhen, Sara
    Oliva, Stefania
    Rodriguez-Otero, Paula
    Kanagavel, Dheepak
    Oprea, Corina
    Wei, Vivian
    Doroumian, Severine
    Martinez-Lopez, Joaquin
    BLOOD, 2017, 130
12345